Although the ICIs monotherapy is associated with improved survival, there is still controversy over whether chemoimmunotherapy or ICIs monotherapy is the first-line treatment for advanced NSCLC patients with high programmed cell death ligand 1(PD-L1) expression [5], which should be revealed in large-scale and well-designed clinical trials. This evidence concerns the gene CD274 and non-small cell lung carcinoma.